Bridgeway Capital Management LLC Lowers Stake in Codexis, Inc. (NASDAQ:CDXS)

Bridgeway Capital Management LLC lessened its holdings in Codexis, Inc. (NASDAQ:CDXS) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 236,008 shares of the biotechnology company’s stock after selling 5,992 shares during the quarter. Bridgeway Capital Management LLC owned about 0.29% of Codexis worth $1,126,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. CenterBook Partners LP purchased a new stake in shares of Codexis in the 4th quarter worth approximately $4,688,000. Tallon Kerry Patrick purchased a new stake in shares of Codexis in the fourth quarter worth $2,018,000. Vanguard Group Inc. increased its holdings in shares of Codexis by 7.5% during the fourth quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company’s stock valued at $21,292,000 after acquiring an additional 311,082 shares in the last quarter. Telemark Asset Management LLC raised its position in shares of Codexis by 11.3% in the 4th quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company’s stock worth $14,310,000 after purchasing an additional 303,589 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Codexis by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company’s stock worth $8,853,000 after purchasing an additional 211,475 shares in the last quarter. Institutional investors own 78.54% of the company’s stock.

Codexis Price Performance

NASDAQ:CDXS opened at $2.46 on Friday. The firm has a 50-day simple moving average of $2.46 and a two-hundred day simple moving average of $3.75. The firm has a market cap of $203.80 million, a P/E ratio of -2.83 and a beta of 2.56. Codexis, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $6.08. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21.

Codexis (NASDAQ:CDXS) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $21.46 million for the quarter, compared to analysts’ expectations of $27.41 million. Analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.